Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02599480
Other study ID # Beta3_LVH V1.0
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date April 2016
Est. completion date September 2022

Study information

Verified date September 2021
Source Université Catholique de Louvain
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the efficacy of mirabegron, a new beta3-adrenergic receptor in the prevention of heart failure. This is a two armed, prospective, randomized, placebo-controlled, multi-centric european phase IIb trial with placebo and mirabegron distributed in a 1:1 fashion. The patients enrolled will have cardiac structural remodeling with or without symptoms of heart failure (maximum NYHA II). Patients will be monitored for change in left ventricular mass (assessed by cardiac MRI) and/or changes in diastolic function (assessed by echocardiography) after 12 months of treatment.


Description:

Background Heart failure (HF) represents a major and growing public health burden. Patients with HF are classically divided into two groups: those with HF with preserved ejection fraction (HFpEF), and those with HF and reduced ejection fraction (HFrEF). As HF is a progressive disorder increasing with age, the proportion of these patients is rising due to the aging of the population. Beside costs, HFpEF also puts a heavy burden on the quality of life of (mostly elderly) patients, with a loss of autonomy and the dyscomfort of repeated hospitalisations. Therefore, HFpEF is a chronic, costly, debilitating disease. A major contributor to HFpEF is myocardial remodelling, e.g. hypertrophy and fibrosis, as well as cellular functional/structural modifications leading to alteration in contractile properties and ventricular distensibility. Unfortunately, there are currently no evidence-based treatment strategies. Study claim The proposed clinical trial will provide a proof of concept in humans for the clinical efficacy of a novel therapeutic concept: β3AR activation to attenuate/prevent cardiac remodeling. Recently, a new, specific agonist at human β3-AR (mirabegron) with higher benefit/risk balance was developed and marketed for clinical use in a non-cardiovascular disease (overactive bladder disease). The trial will test the drug repurposing of mirabegron for the prevention of cardiac remodeling leading to HFpEF. Using pre-clinical models, the investigators demonstrated that activation of β3AR attenuates myocardial hypertrophy and fibrosis in response to neurohormonal or hemodynamic stresses, without compromising LV function. Therefore, the recent availability of this new drug offers the possibility to test the potential benefit of mirabegron (vs placebo) as add-on therapy (on top of standard care) to prevent/delay myocardial remodelling in patients at high risk of developing HFpEF. Who can participate? Patients with structural cardiac disease with or without HF symptoms (max. NYHA 2). What does the study involve? Patients will be requested to go 5 times to the hospital to perform cardiac MRI (3X), echocardiography (3X), exercise tolerance test (2X), Pet scanning (2X) and blood sampling (4X). Who is the sponsor? The Université catholique de Louvain (UCL) is the academic sponsor and Prof. Jean-Luc Balligand is the principal coordinator of the study. Who is funding the study? Beta3_LVH is an investigator-initiated project funded by a Horizon 2020 grant from the European Commission.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 296
Est. completion date September 2022
Est. primary completion date August 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Age between 18 and 90 years - Arterial hypertension on stable therapy according to current guideline algorithms (including stable medication for at least four weeks before inclusion), - Morphological signs of structural cardiac remodelling by echocardiography, i.e. increased LV mass index (110 g/m2 or higher for female; 134 g/m2 or higher for male subjects (Devereux, Reichek 1977)) or end-diastolic wall thickness >13 mm in at least one wall segment - Patients may have atrial fibrillation (AF), but with well-regulated ventricular response, i.e. heart rate<100/min (RACE II - (Groenveld et al. 2013, 2013)), - Written informed consent - For subjects unable to read and/or write, oral informed consent observed by an independent witness is acceptable if the subject has fully understood oral information given by the Investigator. The witness should sign the consent form on behalf of the subject. Exclusion Criteria: - Unstable hypertension with systolic BP=160 mm Hg and/or diastolic BP=100 mm Hg (based on office measurement, not ambulatory measurement) - Documented ischemic cardiac disease - History of hospitalization for overt heart failure within last 12 months - Patients after heart transplantation - Genetic hypertrophic or dilated cardiomyopathy - Dysthyroidism. - Severe valvulopathy - NYHA-class > II - BMI >40 kg/m2 - EF < 50%, regardless of symptoms - Known other cause (i.e. COPD) of respiratory dysfunction; patients under positive pressure (CPAP) treatment for sleep apnea syndrome may be included, provided they have been under regular treatment for at least one year before inclusion in the study - eGFR < 30 ml/min (by MDRD formula) - Abnormal liver function tests - Type I diabetes, complicated type II diabetes - Patients with anemia - Patients with bladder outlet obstruction - Patients using antimuscarinic cholinergic drugs for treatment of OAB - Current use of digitalis, bupranolol, propranolol, nebivolol - Patients continuously treated with Sildenafil or other PDE5 inhibitors. - Current use of antifungal azole derivatives (fluconazole, itraconazole, miconazole, posaconazole, voriconazole) - Current treatment with mirabegron or indication for future treatment with mirabegron due to other indications - Contraindication for MRI - Pregnant or nursing women - Participation in any other interventional trial - Fertile women (within two years of their last menstruation) without appropriate contraceptive measures (hormonal implant, injections, oral contraceptives, intrauterine devices, partner with vasectomy) while participating in the trial (participants using a hormone-based method have to be informed of possible effects from the trial medication on contraception) - Contraindication to mirabegron (e.g. hypersensitivity) or any other components of the trial medication

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
mirabegron
50 mg daily during 12 months
Procedure:
Echocardiography
Echocardiography
Cardiac MRI
Cardiac MRI
Maximal exercise capacity
Maximal exercise capacity
Blood sampling
Blood sampling for study assessments and future exploratory studies.
Endothelial function measurement
EndoPAT assessment
Radiation:
18FDG-PET
PET scanning for beige/brown fat activation

Locations

Country Name City State
Belgium Cliniques universitaires Saint-Luc Brussels
France Nantes university hospital (CHU Nantes) Nantes
Germany Center for Cardiovascular Research Berlin (CCR/Charité) Berlin
Germany University Medical Center Göttingen (UMG-GOE) Göttingen
Greece Athens University Medical School (NKUA) Athens
Italy Hospital "Papa Giovanni XXIII" (HPG23) Bergamo
Poland Department of Heart Diseases at Wroclaw Medical University (UMW) Wroclaw
Portugal Association for Research and Development of the Faculty of Medicine (AIDFM) Lisbon
United Kingdom University of Oxford - Division of Cardiovascular Medicine (UOXF) Oxford

Sponsors (14)

Lead Sponsor Collaborator
Jean-Luc Balligand Center for Cardiovascular Research Berlin, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, European Clinical Research Infrastructure Network, European Commission, European Society of Cardiology, Nantes University Hospital, Northern Lisbon Hospital Center, Papa Giovanni XXIII Hospital, University Medical Center Goettingen, University of Athens, University of Oxford, Wroclaw Medical University, Zentrum für Klinische Studien Leipzig

Countries where clinical trial is conducted

Belgium,  France,  Germany,  Greece,  Italy,  Poland,  Portugal,  United Kingdom, 

References & Publications (3)

Balligand JL. beta(3)-Adrenoceptor stimulation on top of beta(1)-adrenoceptor blockade "Stop or Encore?". J Am Coll Cardiol. 2009 Apr 28;53(17):1539-42. doi: 10.1016/j.jacc.2009.01.048. — View Citation

Belge C, Hammond J, Dubois-Deruy E, Manoury B, Hamelet J, Beauloye C, Markl A, Pouleur AC, Bertrand L, Esfahani H, Jnaoui K, Götz KR, Nikolaev VO, Vanderper A, Herijgers P, Lobysheva I, Iaccarino G, Hilfiker-Kleiner D, Tavernier G, Langin D, Dessy C, Balligand JL. Enhanced expression of ß3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. Circulation. 2014 Jan 28;129(4):451-62. doi: 10.1161/CIRCULATIONAHA.113.004940. Epub 2013 Nov 4. — View Citation

Dessy C, Balligand JL. Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives. Adv Pharmacol. 2010;59:135-63. doi: 10.1016/S1054-3589(10)59005-7. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in left ventricular mass index (LVMI) Change in left ventricular mass index (LVMI in g/m2, defined as left ventricular mass divided by body surface) measured at baseline and 12 months after randomisation. 12 months
Primary Change in diastolic function Change in diastolic function, assessed as the ratio of peak early transmitral ventricular filling velocity to early diastolic tissue Doppler velocity (E/e') measured at baseline and 12 months after randomisation. 12 months
Secondary Cardiac fibrosis Cardiac fibrosis at baseline and at 12 months. Fibrosis is a key pathogenic mechanism of diastolic dysfunction, which is at the origin of HFpEF 12 months
Secondary Left atrial volume index Left atrial volume index at baseline and at 12 months. This parameter determines diastolic filling (and was shown to predict treatment efficacy in HFpEF in the J-DHF trial (Yamamoto et al. 2013)) 12 months
Secondary LV mass index (by cardiac MRI) LV mass index (by cardiac MRI) at 6 months, 6 months
Secondary Diastolic function (E/e') Diastolic function (E/e') at 6 months 6 months
Secondary serum biomarkers serum biomarkers (Galectin3, GDF15, NT-proBNP, hsTnT) 3, 6, 12 months
Secondary metabolic parameters metabolic parameters (fasting glucose, modified HOMA test, HbA1c, serum lipids) 3, 6, 12 months
Secondary Maximal exercise capacity Maximal exercise capacity (peak VO2) at baseline and 12 months. 12 months
Secondary Emergence of treatment-related adverse events Incidence of Treatment-Emergent Adverse Events 12 months
See also
  Status Clinical Trial Phase
Completed NCT02237339 - Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension? Phase 4
Completed NCT00041418 - Cardiac MR of Subclinical CVD: Impact of Age N/A
Completed NCT00005373 - Racial Differences in the Coronary Microcirculation N/A
Recruiting NCT00989508 - Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy Phase 2/Phase 3
Completed NCT03482934 - Predictors of Left Ventricular Hypertrophy in Hypertensive Patients in Assiut Governorate
Completed NCT03415750 - Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants Phase 4
Completed NCT02973607 - Effects of a Reduction in Renal Function on Cardiovascular Structure and Function
Completed NCT03749551 - Towards Understanding the Phenotype of Cardiovascular Disease in CKD - TRUE-Type-CKD Study
Completed NCT01976689 - New-onset Diabetes and Left Ventricular Hypertrophy in Renal Transplantation N/A
Active, not recruiting NCT05713916 - Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy N/A
Recruiting NCT00552851 - Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Phase 4
Active, not recruiting NCT03094143 - Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients With Severe AS N/A
Completed NCT02444689 - EMPower: Electronic Media Powering Positive Health Changes in Youth N/A
Terminated NCT00616902 - The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5 Phase 3
Completed NCT00108082 - The CLEVER Study - Coreg And Left Ventricular Mass Regression Phase 3
Withdrawn NCT03315832 - Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study Phase 2/Phase 3
Completed NCT03180593 - Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH Phase 4
Completed NCT01144039 - Glutamate and Diastolic Function in Patients Undergoing Aortic Valve Repair Phase 4
Completed NCT00045994 - The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling Phase 2
Active, not recruiting NCT04862273 - Native T1 CMR Imaging for Diagnosis of Cardiac Amyloidosis